Beaten-Down Biotech Surges 150% in Pre-Market Trading

A biotech stock that's been struggling is experiencing a dramatic turnaround, jumping 150% in pre-market trading today. The sharp rally suggests significant positive news or a major catalyst has sparked investor interest in the previously beaten-down company. This kind of explosive move often indicates a major development - whether clinical trial results, FDA approval, or strategic partnership - that's reversing the stock's downward trajectory and drawing renewed attention from traders. ---